CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landmark Longitudinal Study in Over 1,000 Transplant Patients Confirms AlloSure More Accurately Measures Organ Health Landmark Longitudinal Study in Over 1,000 Transplant Patients Confirms AlloSure More Accurately Measures Organ Health

CareDx's AlloSure Demonstrates Better Accuracy Than Current Standards of Care in Independent Kidney Transplant Study

Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon's upcoming renal transplantation trials Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon's upcoming renal transplantation trials

CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the third quarter 2021 after market close on Thursday, October 28, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report Third Quarter 2021 Financial Results

AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients AlloSure Significantly Improves Management of High-Risk Lung Transplant Patients

AlloSure, the First dd-cfDNA in Heart and Kidney Transplantation, Launches for Lung Transplant Patients

Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection Multicenter Study Validates AlloMap and Demonstrates the Complementary Value with AlloSure for Detecting Rejection

CareDx Extends Leadership in Multimodality Transplant Care with KidneyCare Validation Publication

False Advertising Lawsuit Against Natera is Set to Go to Trial

CareDx Continues to Fight for Innovation in Transplantation

AlloSeq to be featured in 8 scientific abstracts at ASHI conference AlloSeq to be featured in 8 scientific abstracts at ASHI conference

CareDx Presents Latest Data on AlloSeq Portfolio at ASHI 2021

Gilead Sciences

Novavax

Which subset of the COVID-19 healthcare market will outperform over the next year?

COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?

CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium CareDx announces the launch of AlloSeq cfDNA Research Service and demonstrates global leadership at ESOT with six abstracts and a symposium

CareDx Showcases Leadership in Global Transplantation at ESOT 2021

Why so reliant on M-Ms? Because they have the big-volume-trade clients who need their quick, quiet knowledgeable assistance while managing multi-billion-$ stock portfolios.

CareDx: A Near-Term Capital-Gainer Among Healthcare Diagnostics, Say Market-Makers

CareDx, Inc. (CDNA) CEO Reg Seeto on Q2 2021 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2021.

CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance

ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients

CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

Apple

Vertex Pharmaceuticals

Ardelyx

Array Technologies

International Flavors & Fragrances

Sciplay Corp

Viavi Solutions

With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.

Apple, Array Tech, Vertex Pharma and More Tuesday Afternoon Analyst Calls

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report Second Quarter 2021 Financial Results

AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients

CareDx Transplant Patient App, AlloCare, Expands Access to the Majority of Transplant Patients

Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit

CareDx CEO Reg Seeto to Present at AAKP 4th Annual Policy Summit

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company plans to participate in the Raymond James 2021 Human Health Innovation Conference.

CareDx to Participate in Raymond James 2021 Human Health Innovation Conference

Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development

CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity

KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled

CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance

Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure

CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress

Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems

CareDx Advances Artificial Intelligence in Transplantation

Bloom Energy

NetApp

APA Corporation

AvalonBay Communities

Blade Air Mobility

Enphase Energy

With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.

News for CareDx Stock (CDNA)